Use your antibodies-online credentials, if available.
抗Mouse (Murine) 抗体:
抗Rat (Rattus) 抗体:
Human Monoclonal MFN2 Primary Antibody for IHC (p), RNAi - ABIN564263
Holloway, Perry, Thrush, Heigenhauser, Dyck, Bonen, Spriet: PGC-1alpha's relationship with skeletal muscle palmitate oxidation is not present with obesity despite maintained PGC-1alpha and PGC-1beta protein. in American journal of physiology. Endocrinology and metabolism 2008
Show all 8 Pubmed References
Human Polyclonal MFN2 Primary Antibody for IF (p), IHC (p) - ABIN682528
Ku, Ji, Zhang, Li, Sang: PM2.5, SO2 and NO2 co-exposure impairs neurobehavior and induces mitochondrial injuries in the mouse brain. in Chemosphere 2016
Show all 2 Pubmed References
Human Monoclonal MFN2 Primary Antibody for IHC (p), ELISA - ABIN523306
Stacchiotti, Favero, Giugno, Lavazza, Reiter, Rodella, Rezzani: Mitochondrial and metabolic dysfunction in renal convoluted tubules of obese mice: protective role of melatonin. in PLoS ONE 2014
Mammalian Monoclonal MFN2 Primary Antibody for ISt, IHC - ABIN1304825
Hoppins, Edlich, Cleland, Banerjee, McCaffery, Youle, Nunnari: The soluble form of Bax regulates mitochondrial fusion via MFN2 homotypic complexes. in Molecular cell 2011
Human Monoclonal MFN2 Primary Antibody for IHC (p), WB - ABIN2475579
Minet, Gaster: The dynamic equilibrium between ATP synthesis and ATP consumption is lower in isolated mitochondria from myotubes established from type 2 diabetic subjects compared to lean control. in Biochemical and biophysical research communications 2011
Cow (Bovine) Polyclonal MFN2 Primary Antibody for IHC, WB - ABIN2775408
Chung, Cho, Hwang, Kim, Yoo, Kwon, Kim, Sunwoo, Züchner, Choi: Early-onset stroke associated with a mutation in mitofusin 2. in Neurology 2008
Show all 2 Pubmed References
Human Polyclonal MFN2 Primary Antibody for IHC, IHC (p) - ABIN4334778
Yang, Yang: Bit-by-bit autophagic removal of parkin-labelled mitochondria. in Nature communications 2013
Human Monoclonal MFN2 Primary Antibody for ELISA, WB - ABIN5326795
Sawyer, Cheuk-Him Ng, Innes, Wagner, Dyment, Tetreault, Majewski, Boycott, Screaton, Nicholson: Homozygous mutations in MFN2 cause multiple symmetric lipomatosis associated with neuropathy. in Human molecular genetics 2015
Enhancing the profusion gene mitofusin/marf is beneficial in an in vivo model of TDP-43 (显示 TARDBP 抗体) proteinopathies, serving as a potential therapeutic target.
activation of endoplasmic reticulum stress by defective mitochondria is neurotoxic in pink1 (显示 PINK1 抗体) and parkin (显示 PARK2 抗体) flies and that the reduction of this signalling is neuroprotective, independently of defective mitochondria.
Clu (显示 CLU 抗体) is upstream of and binds to VCP (显示 vcp 抗体) in vivo and promotes VCP (显示 vcp 抗体)-dependent Marf degradation in vitro Marf accumulates in whole muscle lysates of clu (显示 CLU 抗体)-deficient flies and is destabilized upon Clu (显示 CLU 抗体) overexpression. Thus, Clu (显示 CLU 抗体) is essential for mitochondrial homeostasis and functions in concert with Parkin (显示 PARK2 抗体) and VCP (显示 vcp 抗体) for Marf degradation to promote damaged mitochondrial clearance.
lack of ChChd3 (显示 CHCHD3 抗体) leads to inactivation of Hippo activity under normal development, which is also dependent on the transcriptional coactivator Yorkie (Yki (显示 YAP1 抗体)). Furthermore, loss of ChChd3 (显示 CHCHD3 抗体) induces oxidative stress and activates the JNK (显示 MAPK8 抗体) pathway. In addition, depletion of other mitochondrial fusion components, Opa1 (显示 OPA1 抗体) or Marf, inactivates the Hippo pathway as well.
Marf is required for mitochondrial fusion and transport in long axons.
Expression of Mfn2 and endoplasmic reticulum (ER) stress reduction in flies lacking Marf corrected ER shape, attenuating the developmental and motor defects.
Parkin (显示 PARK2 抗体) deficiency and resulting mitophagic disruption produces cardiomyopathy which can be contained by suppressing mitofusin.
mfn2 mutations alter mitochondrial dynamics and induce retinal and cardiac pathology
Data report here that Drosophila Reaper can induce mitochondrial fragmentation by binding to and inhibiting the pro-fusion protein MFN2 and its Drosophila counterpart dMFN/Marf.
MARF and Opa1 (显示 OPA1 抗体) control mitochondrial and cardiac function in Drosophila.
Our patient with MFN2-related CMT2 expands the clinical and mutational spectrum of individuals with autosomal recessive CMT2 and identifies a new clinical feature that warrants further observation.
It has been shown that mitofusin-2 is modified with K6-linked polyubiquitin in a HUWE1-dependent manner.
Studied association of genetic variants of the MAVS, MITA and MFN2 genes with leprosy in Han Chinese from Southwest China; found no association between the variants and susceptibility to leprosy.
MFN2 gene polymorphisms (rs873457, rs2336384, rs1474868, rs4846085 and rs2236055) may be associated with acute liver failure and the rs873457 and rs4846085 polymorphisms are correlated with the risk and prognosis of acute liver failure.
SLC25A46 (显示 SLC25A46 抗体) is a new component in mitochondrial dynamics that serves as a regulator for MFN1 (显示 MFN1 抗体)/2 oligomerization.
Presenilin 2 (PS2 (显示 PSEN2 抗体)), mutations in which underlie familial Alzheimer's disease (FAD (显示 BRCA2 抗体)), promotes endoplasmic reticulum-mitochondria coupling only in the presence of mitofusin 2 (Mfn2).
PGC-1alpha (显示 PPARGC1A 抗体) enhances Mfn2 transcription, but also leads to increased degradation of the Mfn2 protein, a key ubiquitylation target of Parkin (显示 PARK2 抗体) on mitochondria. In vivo, Parkin (显示 PARK2 抗体) has significant protective effects on the survival and function of nigral dopaminergic neurons in which the chronic expression of PGC-1alpha (显示 PPARGC1A 抗体) is induced
Exome sequencing identified MFN2 SNVs in two of the individuals. Neuropathy-associated CNV outside of the PMP22 (显示 PMP22 抗体) locus is rare in Charcot-Marie-Tooth (CMT) disease . Nevertheless, there is potential clinical utility in testing for CNVs and exome sequencing in CMT cases negative for the CMT1A (显示 PMP22 抗体) duplication.
Smad2 (显示 SMAD2 抗体) is a key scaffold, allowing RIN1 (显示 RIN1 抗体) to act as a GTP (显示 AK3 抗体) exchange factor for MFN2-GTPase (显示 RACGAP1 抗体) activation to promote mitochondrial ATP synthesis and suppress superoxide production during mitochondrial fusion.
our results suggest that KAP1 (显示 CDKN3 抗体) Ser473 phosphorylation acts through MFN2 reduction to restrict mitochondrial hyperfusion, thereby contributing to cancer cell survival under conditions of sustained metabolic stress
Despite apparent mitochondrial dysfunction, hearts deficient in both Mfn1 (显示 MFN1 抗体) and Mfn2 are protected against acute myocardial infarction due to impaired mitochondria/sarcoplasmic reticulum tethering.
Presenilin 2 (PS2 (显示 PSEN2 抗体)), mutations in which underlie familial Alzheimer's disease (FAD (显示 FANCD2 抗体)), promotes endoplasmic reticulum-mitochondria coupling only in the presence of mitofusin 2 (Mfn2).
The data of this study suggest that post-translational modification of Mfn2 is associated with its dysregulation during a window of metabolic vulnerability that precedes glaucomatous degeneration.
Study demonstrated that deregulation of mfn2 played a critical role in the mitochondrial disorder during the progression of Alzheimer's disease, and its decreased expression was regulated at least in part by miR (显示 MLXIP 抗体)-195. Therefore, upregulation of mfn2 expression by decreasing the level of miR (显示 MLXIP 抗体)-195 might be a potential new therapeutic strategy for treatment of Alzheimer's disease.
Mfn2 downregulation or the exogenous expression of normal Parkin (显示 PARK2 抗体) restored cytosolic Ca(2 (显示 CA2 抗体)+) transients in fibroblasts from patients with PARK2 (显示 PARK2 抗体) mutations, a catalytically inactive Parkinson's disease (PD)-related Parkin (显示 PARK2 抗体) variant had no effect. Parkin (显示 PARK2 抗体) is directly involved in regulating ER-mitochondria contacts and provide new insight into the role of the loss of Parkin (显示 PARK2 抗体) function in PD development.
Altogether, these results demonstrate that Mfn2 is a mediator of mitochondria to lipid droplet interactions, influencing lipolytic processes and whole-body energy homeostasis.
we demonstrated that by modulating mitochondrial energy metabolism through Mfn2 and mitochondrial Ca2 (显示 CA2 抗体)+, PPAR-b (显示 PPARD 抗体) took an important role in neuronal differentiation induced by flavonoid compound 4a
Furthermore, analysis of muscle Mfn2-deficient mice revealed that aging-induced Mfn2 decrease underlies the age-related alterations in metabolic homeostasis and sarcopenia.
Mice hemizygous for a pathogenic Mfn2 allele exhibit hind limb/foot gait deficits and phenotypic perturbations in nerve and muscle.
We found that mouse embryonic fibroblasts lacking Mfn2 have altered lipid droplet morphology. However, triacylglycerol biosynthesis was not dependent on ER-mitochondrial tethering mediated by mitofusins. Lastly, Mfn2 does not have a role in adipocyte differentiation.
MFN2 mutation status should be investigated in patients presenting with early-onset recessively inherited axonal CMT
These results highlight the essential role of mitofusin 2 in the motor axon development and demonstrate the potential of zebrafish as a suitable and complementary platform for dissecting pathogenetic mechanisms of MFN2 mutations in vivo.
A highly unusual splicing defect, where an exonic single base exchange leads to the retention of the preceding intron, was identified in MFN2 (显示 MFN1 抗体).
This gene encodes a mitochondrial membrane protein that participates in mitochondrial fusion and contributes to the maintenance and operation of the mitochondrial network. This protein is involved in the regulation of vascular smooth muscle cell proliferation, and it may play a role in the pathophysiology of obesity. Mutations in this gene cause Charcot-Marie-Tooth disease type 2A2, and hereditary motor and sensory neuropathy VI, which are both disorders of the peripheral nervous system. Defects in this gene have also been associated with early-onset stroke. Two transcript variants encoding the same protein have been identified.
, drosophila mitofusin
, mitochondrial assembly regulatory factor
, mitofusin 2
, hyperplasia suppressor
, transmembrane GTPase MFN2
, HSG protein
, hypertension related protein 1
, hypertension-related protein 1
, hypertension-related protein
, mitochondrial transmembrane GTPase FZO1A